Amador BioSciences

8 articles about Amador BioSciences

• Translational Science Is the Key to the Success of the Clinical Research

  12/5/2023

  In Q2 2023, Amador Bioscience, a next generation CRO focusing on translational science and early clinical development, announced the addition of Dr. Lorin Roskos to the Board of Directors.

• Amador Bioscience Welcomes Dr. Lorin Roskos as Chief Scientific Officer and President of Quantitative Clinical Pharmacology

  5/5/2023

  Amador Bioscience has announced the appointment of Dr. Lorin Roskos as Chief Scientific Officer (CSO) and President of Quantitative Clinical Pharmacology (QCP).

• Dr. Lorin K Roskos, Biopharmaceutical Leader and Executive, Joins Amador Bioscience's Board of Directors

  3/7/2023

  Amador Bioscience, a full-service CRO with global expertise in translational research and clinical development, announces the appointment of Lorin K Roskos, PhD, to its board of directors, effective immediately.

• Dr. Nidal Huniti joins A2PG as President

  5/3/2022

  A2PG and Amador Bioscience announced that Dr. Nidal Huniti has joined the company as President of A2PG.

• 

  Money on the Move: December 29 – January 4

  1/5/2022

  Here's who rang in the New Year by joining the NASDAQ or raising private equity funds.

• Amador Bioscience Announces the Completion of $60 Million Series B+ Round Financing

  12/30/2021

  Amador Bioscience announced today that it has completed 60MM USD Series B+ financing led by MSA Capital, a global private equity firm .  

• Amador Bioscience completed the acquisition of Ann Arbor Pharmacometrics Group (A2PG)

  12/24/2021

  Amador Bioscience announced today that it has completed the acquisition of Ann Arbor Pharmacometrics Group ( A2PG), a premier pharmacometrics consulting firm based in Ann Arbor, Michigan.

• Institutional Investors Co-Led Series B Financing of Amador Bioscience, a Global Translational Sciences and Clinical Pharmacology CRO

  9/28/2021

  Amador Bioscience, a contract research organization that provides global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies, announced the completion of Series B financing to support its further global expansion.